Sanofi: Investing in prevention builds Europe's health and competitiveness

Core Insights - The Polish Presidency of the EU Council emphasizes health policy as a central element of Europe's strategic agenda, focusing on healthcare resilience and digital transformation [1] - Sanofi advocates for a shift from reactive treatment to proactive prevention strategies, highlighting the economic benefits of investing in prevention [2] - The importance of innovation in healthcare systems is underscored, with a call to close the innovation gap and adopt advanced technologies for Europe's long-term prosperity [3][4] Group 1: Prevention and Economic Impact - Sanofi's investment in prevention yields significant returns, with every €1 invested bringing €14 back, and up to €19 for adult immunization [2] - Real-world evidence shows an 80% reduction in winter hospitalizations among infants due to RSV immunization, emphasizing the effectiveness of prevention [2] - Chronic respiratory diseases are a major public health concern in Europe, affecting over 36 million people and accounting for 6% of healthcare expenditure [2] Group 2: Innovation and Competitiveness - The need for Europe to rebuild its leadership in pharmaceutical innovation is critical, as global R&D investments are shifting away [4] - Collaboration between industry and academia, support for emerging biotechnologies, and a conducive regulatory environment are essential for fostering innovation [4] - Digital health and data-driven research are highlighted as transformative elements for strengthening healthcare systems and economic future [3] Group 3: Human Dimension of Innovation - Scientific progress must translate into improved lives for individuals and communities, with a focus on immunization as a key tool [5][6] - The mission is to transition healthcare from treatment to prevention, with immunization saving 154 million lives globally over the past 50 years [6] - Prevention and immunization should be viewed as economic stabilizers, emphasizing the need for a model built on innovation and long-term strength [7]